| Primary |
| Non-hodgkin's Lymphoma |
58.9% |
| Drug Use For Unknown Indication |
13.3% |
| Lymphoma |
8.3% |
| Mantle Cell Lymphoma |
3.9% |
| Multiple Myeloma |
3.3% |
| Product Used For Unknown Indication |
2.8% |
| Anxiety |
1.1% |
| B-cell Lymphoma |
1.1% |
| Depression |
1.1% |
| Diffuse Large B-cell Lymphoma |
1.1% |
| Accidental Exposure |
0.6% |
| B-cell Small Lymphocytic Lymphoma |
0.6% |
| Blood Stem Cell Transplant Failure |
0.6% |
| Cough |
0.6% |
| Deep Vein Thrombosis |
0.6% |
| Immunosuppressant Drug Therapy |
0.6% |
| Pruritus |
0.6% |
| Skin Lesion |
0.6% |
| Thyroid Disorder |
0.6% |
|
| Pyrexia |
11.9% |
| Weight Decreased |
9.0% |
| Pneumonia |
7.5% |
| Rash |
7.5% |
| White Blood Cell Count Decreased |
7.5% |
| Cellulitis |
4.5% |
| Death |
4.5% |
| Disease Progression |
4.5% |
| Lymphoma |
4.5% |
| Myelodysplastic Syndrome |
4.5% |
| Neuropathy |
4.5% |
| Rash Generalised |
4.5% |
| Thrombocytopenia |
4.5% |
| Agranulocytosis |
3.0% |
| Anaemia |
3.0% |
| Bone Marrow Failure |
3.0% |
| Drug Ineffective |
3.0% |
| Dyspnoea |
3.0% |
| Human Anti-mouse Antibody Positive |
3.0% |
| Lymphadenopathy |
3.0% |
|
| Secondary |
| Non-hodgkin's Lymphoma |
49.1% |
| Drug Use For Unknown Indication |
21.1% |
| Product Used For Unknown Indication |
9.6% |
| Mantle Cell Lymphoma |
5.3% |
| Multiple Myeloma |
3.5% |
| Lymphoma |
2.6% |
| Pruritus |
2.6% |
| Anxiety |
1.8% |
| Depression |
1.8% |
| Diffuse Large B-cell Lymphoma |
1.8% |
| Infection Prophylaxis |
0.9% |
|
| White Blood Cell Count Decreased |
12.1% |
| Infusion Related Reaction |
9.1% |
| Rash |
9.1% |
| Weight Decreased |
9.1% |
| Myelodysplastic Syndrome |
6.1% |
| Pyrexia |
6.1% |
| Syncope |
6.1% |
| Viith Nerve Paralysis |
6.1% |
| Anaemia |
3.0% |
| Cellulitis |
3.0% |
| Drug Hypersensitivity |
3.0% |
| Febrile Neutropenia |
3.0% |
| Hypotension |
3.0% |
| Neutropenia |
3.0% |
| Non-cardiac Chest Pain |
3.0% |
| Pancytopenia |
3.0% |
| Pleural Effusion |
3.0% |
| Pneumonia |
3.0% |
| Pneumonia Streptococcal |
3.0% |
| Progressive Multifocal Leukoencephalopathy |
3.0% |
|
| Concomitant |
| Drug Use For Unknown Indication |
73.7% |
| Non-hodgkin's Lymphoma |
21.1% |
| Product Used For Unknown Indication |
5.3% |
|
| Urinary Tract Infection |
50.0% |
| Cardiac Failure Congestive |
25.0% |
| Non-hodgkin's Lymphoma |
25.0% |
|
